Introduction {#section5-1470320316659954}
============

Systemic Sclerosis (SSc) is a systemic autoimmune connective tissue disorder characterized by inflammation, fibrosis and obliterative vasculopathy.^[@bibr1-1470320316659954]^ There are two clinical subsets of SSc described, based on the extent of cutaneous involvement: diffuse (dc) and limited cutaneous (lc) SSc.^[@bibr2-1470320316659954]^ These subtypes exhibit different profiles of autoantibodies, which also vary among populations.^[@bibr3-1470320316659954][@bibr4-1470320316659954][@bibr5-1470320316659954][@bibr6-1470320316659954][@bibr7-1470320316659954][@bibr8-1470320316659954][@bibr9-1470320316659954]--[@bibr10-1470320316659954]^

We have described that the prevalence of autoantibodies in Mexican SSc patients is different from that of other populations; that there is a higher prevalence of anti-topoisomerase I, anti-PM-Scl and anti-Ku antibodies and that there is a lower prevalence of anti-RNA polymerase III antibodies than in other populations.^[@bibr10-1470320316659954]^ These phenotypic variations are influenced by genetic background. For instance, the variability in the major histocompatibility complex (MHC) genes influences the persons' susceptibility to develop SSc and disease expression in different ethnic groups.^[@bibr11-1470320316659954][@bibr12-1470320316659954][@bibr13-1470320316659954][@bibr14-1470320316659954][@bibr15-1470320316659954][@bibr16-1470320316659954]--[@bibr17-1470320316659954]^

Vascular involvement is a primary event in SSc pathogenesis. Studies of angiotensin converting enzyme (ACE) and endothelial nitric oxide synthase (eNOS) polymorphisms suggest that specific alleles are associated with scleroderma^[@bibr18-1470320316659954]^; however, there is no information about the role of these and other polymorphisms being involved the renin-angiotensin-aldosterone system (RAAS) in Mexican admixed SSc patients (defined as patients with Mexican ancestry for at least 3 generations). This study will identify the influence of these polymorphisms in the presence and severity of internal organ damage in this patient population.

Patients and methods {#section6-1470320316659954}
====================

Subjects {#section7-1470320316659954}
--------

We evaluated 15 functional single nucleotide polymorphisms (SNPs) in angiotensin-converting enzyme (ACE), angiotensin II Type 1 receptor (AGTR1) and endothelin 1 genes (Supplementary Table 1), in a group of 170 Mexican admixed SSc patients (77 dcSSc and 93 lcSSc) without overlap syndromes, and in 199 ethnically matched healthy controls.

Patients fulfilled the 2013 classification criteria for SSc^[@bibr19-1470320316659954]^ or LeRoy-Medsger criteria for early SSc.^[@bibr20-1470320316659954]^ All patients were evaluated by one rheumatologist, who was responsible for the scleroderma cohort, between July 2007 and July 2010 at the *Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán* (INCMNSZ), a referral center in Mexico City, Mexico. Patients were classified as dcSSc or lcSSc (skin involvement above the elbows or knees, or including chest or abdomen, at any time during the illness for the diffuse disease; and distal to the elbows or knees for the limited disease).^[@bibr10-1470320316659954]^ Organ involvement attributable to SSc was also determined using previously published definitions.^[@bibr21-1470320316659954]^ The severity of each organ manifestation was determined according to the Medsger severity scale, at the time of the inclusion of the patient to this study; scores of 3--4 for each organ system were considered as severe involvement.^[@bibr21-1470320316659954]^

### Ethics statement {#section8-1470320316659954}

Local Institutional Review Boards (IRBs) approved the study. All subjects provided written informed consent for collection of clinical data, serum and DNA samples. All patients were at least 18 years old. This study was carried out in accordance with the World Medical Association Declaration of Helsinki.

SSc-specific autoantibodies {#section9-1470320316659954}
---------------------------

Peripheral venous blood was obtained to isolate serum (frozen at −70°C until processing) and we tested it for SSc-associated antibodies, according to the manufacturers' recommendations: the antinuclear IgG antibodies were detected by indirect immunofluorescence using a Hep-2 cell substrate (The Binding Site, Birmingham, UK)^[@bibr10-1470320316659954]^ ; the IgG isotype anti-topoisomerase-I, anticentromere B, anti-U1 RNP (The Binding Site, UK) and anti-RNA polymerase III (INOVA Diagnostics, San Diego, CA, USA) were detected by immunoenzymatic assay (EIA). For the anticentromere A, anti-U3 RNP, anti-U11/U12 RNP, anti-PM-Scl, anti-Th/To and anti-Ku antibodies, a commercial Western blot was performed using Hep-2 whole cell extract and recombinant centromere A, U3 RNP, U11/U12 RNP, PM-Scl, Th/To and Ku proteins (Euroimmun, Lübeck, Germany).

SNP analysis {#section10-1470320316659954}
------------

Genomic DNA was isolated from peripheral blood mononuclear cells (PBMCs). SNPs were genotyped using 5' exonuclease TaqMan genotyping assays on a 7900HT fast real-time PCR system (Applied Biosystems, Foster City, CA, USA). Each genotype was defined with the allelic discrimination software (7300 System SDS Software by Applied Biosystems, USA).

Statistical analysis {#section11-1470320316659954}
--------------------

Demographic and clinical variables were analyzed with SPSS v15. We tested for the Hardy-Weinberg equilibrium for all genotypic combinations of each SNP, in patients and controls. We evaluated the differences in the distribution of the allelic and genotypic frequencies using the Mantel-Haenszel Chi-square test (EPIINFO v6.04b). We used a significance level of *p* \< 0.05, with Bonferroni correction. Odds ratios (OR) with 95% CI were estimated. We performed logistic regression analyses in the variables that showed *p* values of \< 0.1 for SNP association, to adjust for confounding variables.

Results {#section12-1470320316659954}
=======

Demographic and clinical characteristics are shown in [Table 1](#table1-1470320316659954){ref-type="table"}. There were more male patients in the dcSSc (13%) group than in the lcSSc group (3%; *p* = 0.01). Tendon and joint involvement (*p* = 0.001), gastrointestinal damage (*p* = 0.01) and interstitial lung disease (*p* = 0.005) were more frequent in dcSSc than lcSSc patients.

###### 

Clinical and serological characteristics of patients with SSc.^[a](#table-fn1-1470320316659954){ref-type="table-fn"}^

![](10.1177_1470320316659954-table1)

                                                                                   Total *n* = 170 (%)   dcSSc *n* = 77 (%)   lcSSc *n* = 93 (%)   *p* value
  -------------------------------------------------------------------------------- --------------------- -------------------- -------------------- ---------------------
  Female gender                                                                    157 (92)              67 (87)              90 (97)              0.01
  Age (mean)                                                                       45.1 ± 14.8           42.5 ± 13.9          47.7 ± 15.1          0.02
  Time of evolution (mean)                                                         11 ± 9.7              8 ± 6                13 ± 1.1             0.001
  Vascular                                                                         155 (91)              73 (95)              82 (88)              0.37
  Severe vascular^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^           79 (46)               41 (53)              38 (41)              0.19
  Tendons/joints                                                                   116 (68)              63 (82)              53 (57)              0.001
  Severe^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^ tendons/joints     29 (17)               18 (23)              11 (12)              0.04
  Muscular                                                                         26 (15)               13 (17)              13 (17)              0.6
  Severe^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^ muscular           2 (1)                 1 (1)                1 (1)                0.8
  Gastrointestinal                                                                 118 (69)              61 (79)              57 (61)              0.01
  Severe^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^ gastrointestinal   7 (4)                 5 (6.5)              2 (2)                0.15
  ILD                                                                              77 (45)               44 (57)              33 (35)              0.005
  Severe^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^ ILD                12 (7)                8 (10)               4 (4)                0.11
  PAH                                                                              42 (25)               23 (30)              19 (20)              0.13
  Severe^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^ PAH                6 (3.5)               3 (4)                3 (3)                0.8
  Heart                                                                            23 (13)               12 (16)              11 (12)              0.29
  Severe^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^ heart              3 (2)                 1 (1)                2 (2)                0.9
  Renal                                                                            2 (1)                 1 (1)                1 (1)                0.6
  Severe^[b](#table-fn2-1470320316659954){ref-type="table-fn"}^ renal              2 (1)                 1 (1)                1 (1)                0.2
  Comorbidities                                                                    Total *n* = 170 (%)   dcSSc *n* = 77 (%)   lcSSc *n* = 93 (%)   *p* value
  Diabetes mellitus                                                                9 (5.2)               4 (5)                5 (5)                0.9
  Systemic arterial hypertension                                                   19 (11)               6 (8)                13 (14)              0.19
  Dyslipidemia                                                                     19 (11)               7 (9)                12 (13)              0.41
  Current tobacco use                                                              12 (7)                6 (8)                6 (6.5)              0.7
  Past tobacco use                                                                 37 (22)               23 (30)              14 (15)              0.02
  Coronary artery disease                                                          8 (5)                 3 (4)                5 (5)                0.64
  Cerebral vascular disease                                                        1 (0.6)               0 (0)                1 (1)                0.3
  Anti-phospholipid antibody syndrome                                              3 (2)                 0 (0)                3 (3.2)              0.11
  Anti-phospholipid antibody positive                                              36 (21)               15 (19.5)            21 (23)              0.86
  SSc-associated autoantibodies                                                    Total *n* = 170 (%)   dcSSc *n* = 77 (%)   lcSSc *n* = 93 (%)   Total *n* = 170 (%)
  Anti-centromere                                                                  43 (25)               15 (19.5)            28 (30)              0.09
  Anti-topoisomerase I                                                             38 (22)               32 (42)              6 (6.5)              0.0009
  Anti-U1-RNP                                                                      27 (16)               5 (6.5)              22 (24)              0.002
  Anti-PM-Scl                                                                      10 (6)                5 (6.5)              5 (5)                0.8
  Anti-RNA-Pol III                                                                 1 (0.6)               0 (0)                1 (1)                0.9
  Anti-Ku                                                                          11 (6.5)              4 (5)                7 (7.5)              0.5
  Only positive ANA                                                                38 (22)               15 (19.5)            23 (25)              0.4
  No detectable autoantibody                                                       2 (1)                 1 (1)                1 (1)                0.9

Data are expressed as means ± SD, means and percentage or *n* and percentage.

Items marked as 'severe' are those with Medsger Severity Scale scores of 3 or 4.

ANA: anti-nuclear antibodies; dcSSc: diffuse cutaneous systemic sclerosis; ILD: interstitial lung disease; Anti-Ku: anti-Ku antibodies; lcSSc: limited cutaneous systemic sclerosis; PAH: pulmonary arterial hypertension; Anti-PM-Scl: anti-PM-Scl antibodies; Anti-RNA-Pol III: anti-RNA-Pol III antibodies; Anti-UI-RNP: anti-UI-RNP antibodies; SSc: systemic sclerosis.

AGTR1, ACE and endothelin 1 polymorphisms had similar distributions between SSc patients and controls (Supplementary Table 2), and between diffuse and limited SSc patients (Supplementary Table 3); however, the analysis of these polymorphisms by internal organ involvement revealed that there were some differences in AGTR1 SNPs.

AGTR1-680 and -119 SNPs were associated with severe vascular involvement in SSc patients {#section13-1470320316659954}
----------------------------------------------------------------------------------------

[Table 2](#table2-1470320316659954){ref-type="table"} and Supplementary Table 4 show a significant increase in the genotype frequency of the heterozygous G/T genotype of the AGTR1 G-680T polymorphism (rs275652) in the group of SSc patients with severe vascular involvement (presence ever of digital tip ulcers and/or digital gangrene, according to the Medsger Severity Scale^[@bibr21-1470320316659954]^; g.f. = 0.220), when compared with SSc patients without severe vascular involvement (g.f. = 0.050; pC = 0.006; OR = 5.2 and 95%CI = 1.6--16.2). Accordingly, we observed a significant association of the G allele with severe vascular involvement (pC = 0.02; OR = 3.3 and 95% CI = 1.2--9.1).

###### 

Association of the AGRT1 G-680 T and AGRT1 A-119 G polymorphisms with severe vascular damage in SSc patients.

![](10.1177_1470320316659954-table2)

  Gene                      Severe vascular involvement (*n* = 79)   No severe vascular involvement (*n* = 80)   pC value, OR, 95% CI         *p*^[a](#table-fn4-1470320316659954){ref-type="table-fn"}^ value after logistic regression, OR, 95% CI
  ------------------------- ---------------------------------------- ------------------------------------------- ---------------------------- --------------------------------------------------------------------------------------------------------
  AGTR1 G-680T (rs275652)                                                                                                                     
  Genotypes                 *n* (g.f.)                                                                                                        
  GG                        0                                        2 (0.025)                                   0.49                         
  GT                        17 (0.220)                               4 (0.050)                                   0.006, OR 5.2 (1.6--16.2)    0.02, OR 3.5, (1.2--10.4)
  TT                        62 (0.780)                               74 (0.925)                                  0.02, OR 0.3 (0.1--0.8)      NS
  Alleles                   *n* (a.f.)                                                                                                        
  G                         17 (0.108)                               8 (0.050)                                   0.02, OR 3.3 (1.2--9.1)      
  T                         141 (0.892)                              152 (0.950)                                 0.49, OR 2.01 (1.7--2.3)     
  AGTR1 A-119G (rs275653)                                                                                                                     
  Genotypes                 *n* (g.f.)                                                                                                        
  GG                        0                                        2 (0.025)                                   0.49                         
  AG                        19 (0.241)                               4 (0.050)                                   0.001, OR 6 (1.9--18.6)      0.008, OR 4.2 (1.5--12.1)
  AA                        60 (0.759)                               74 (0.925)                                  0.008, OR 0.26 (0.09--0.7)   
  Alleles                   *n* (a.f.)                                                                                                        
  G                         19 (0.120)                               8 (0.050)                                   0.008, OR 3.9 (1.4--10.4)    
  A                         139 (0.880)                              152 (0.950)                                 0.04, OR 0.39 (0.15--0.97)   

Associations in this column were tested using logistic regression adjusting for age, gender, arterial hypertension, dyslipidemia and Type 2 diabetes mellitus.

AGTR1: angiotensin II Type I receptor; a.f.: allele frequency, g.f.: genotype frequency; pC: corrected *p* value (by Bonferroni).

The analysis of the AGTR1 A-119G polymorphism (rs275653) showed ([Table 2](#table2-1470320316659954){ref-type="table"}) a higher frequency of the A/G heterozygous genotype in the group of SSc patients with severe vascular involvement (g.f. = 0.241 versus g.f. = 0.050 in the SSc patients without severe vascular damage, pC = 0.001, OR = 6.0 and 95%CI = 2.0--18.6). In concordance, we detected a significant increase in the frequency of the G allele in the severe vascular involvement group (pC = 0.008; OR = 3.9 and 95%CI = 1.4--10.4).

Importantly, we confirmed these associations by logistic regression analysis after adjustment for age, gender, arterial hypertension, dyslipidemia and Type II diabetes mellitus ([Table 2](#table2-1470320316659954){ref-type="table"}).

Discussion {#section14-1470320316659954}
==========

Here we studied the prevalence of RAAS polymorphisms and described, for the first time, their associations with organ involvement in Mexican admixed SSc patients. The most significant findings confirmed by logistic regression analysis were the associations of the heterozygous genotypes GT of the SNP AGTR1-680 (rs275652) and AG of the SNP AGTR1-119 (rs275653) with severe vascular damage in SSc patients. These polymorphisms are located in the promoter region of the AGTR1 gene on chromosome 3q21-25. Genetic variations of this gene have been associated with the susceptibility to different diseases.^[@bibr23-1470320316659954][@bibr24-1470320316659954][@bibr25-1470320316659954]--[@bibr26-1470320316659954]^

The AGTR1 gene encodes the Type 1 angiotensin II receptor, which is thought to mediate the major cardiovascular effects of angiotensin II (induction of aldosterone synthesis, increase of water and salt resorption, and potassium excretion in the kidney and increase in blood pressure). Multiple alternatively spliced transcript variants have been reported for this gene.^[@bibr27-1470320316659954]^

Several mechanisms are involved in vascular injury in SSc, including the effect of auto-antibodies against endothelial cells, autoreactive T cells, impaired vasculogenesis and endothelial dysfunction that promotes tissue hypoxia and fibrosis.^[@bibr28-1470320316659954]^

It is well known that alterations in the signaling of the renin-angiotensin-aldosterone system also contribute to vascular injury, inflammation and remodeling in diseases like hypertension, atherosclerosis and cardiac failure. The chronic inflammatory state in the vascular wall contributes to the endothelial impairment that results in increased inflammatory infiltrate and tissue injury.^[@bibr27-1470320316659954]^ Administration of losartan, an angiotensin II receptor 1 (ATR1) antagonist, inhibits Ang II-induced NF-κB activation and vascular cell adhesion molecule 1 (VCAM-1) accumulation,^[@bibr29-1470320316659954]^ suppresses the function of toll-like receptors (TLR)^[@bibr30-1470320316659954]^ 2 and 4 (TLR2 and TLR4) and the production of inflammatory mediators, such as C-reactive protein (CRP) and interleukin 6 (IL-6).^[@bibr31-1470320316659954]^ In this regard, it is well known that SSc patients show increased levels of VCAM-1 in vascular tissue, and elevated serum CRP and IL-6 levels.^[@bibr28-1470320316659954]^

Recent reports demonstrate that there is a significant decrease of Sma mothers against decapentaplegic (SMAD) 2/3 (Smad2/3) molecules, collagen concentration and alpha smooth muscle actin (α-SMA) expression in an experimental mouse SSc model treated with irbesartan.^[@bibr32-1470320316659954]^ It is also known that exposure to the transforming growth factor beta (TGF-B) of lung fibroblasts from patients with lung fibrosis strongly induces the expression of AGTR1^[@bibr33-1470320316659954]^; hence, polymorphisms in this pathway may modulate the expression of inflammatory and vascular abnormalities.^[@bibr34-1470320316659954]^ Moreover, variants of polymorphisms that are located in the AGTR1 gene promoter region could modulate the expression of AGTR1 mRNA levels, or influence alternative splicing in target cells in SSc patients. The over-expression of AGTR1 mRNA could promote increased vasoconstrictive effects of angiotensin II, and possibly contribute to the development of vascular hypoxia, injury and fibrosis in SSc patients. It is interesting to note that the AGTR1-680 (rs275652) and AGTR1-119 (rs275653) polymorphisms were not associated with the SSc itself, but with the presence of severe vascular disease (patients with the presence or history of ischemic digital tip ulcers and/or necrosis); hence, it seems that the susceptibility variants of these polymorphisms confer additional risk for developing a severe form of vasculopathy in SSc patients.

Our study has some limitations, including its relatively small sample size, restricted by the study's focus on SSc patients from Mexican admixed ancestry, and the lack of functional assays to determine the effects of the AGTR1 gene variation in severe vascular involvement in SSc patients and healthy controls; however, one of this study's strengths included the analysis of the influence of AGTR1 promoter polymorphisms in an adequately characterized cohort of Mexican SSc patients and healthy controls.

In summary, our results suggest that the polymorphisms rs275652 and rs275653, located in the promoter region of the AGTR1 gene, may contribute to SSc patients' susceptibility to severe vascular involvement.

Supplementary Material
======================
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